Arikayce (amikacin liposome inhalation suspension)
Insmed (INSM)
Decision dateJan 28, 2027
74 days away
Marketer take
The company says it would launch under an expanded MAC lung disease label, which would widen the pulmonologist and ID audience beyond the current refractory-patient label.
- Sponsor company
- Insmed (INSM)
- Indication
- Expanded label in MAC lung disease (sNDA, priority review)
- Therapeutic area
- Pulmonology, Infectious disease
- Event
- PDUFA target action date
- Date
- Jan 28, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?